
- #AMBIFY ANDROID HOW TO#
- #AMBIFY ANDROID ANDROID#
- #AMBIFY ANDROID TRIAL#
Here is the most recent label, at time of writing. Labels change over time, and the current label should always be consulted.
#AMBIFY ANDROID ANDROID#
Labels are also available using the app for Apple or Android devices. Medication labels can be found by searching at the FDA website. Prescribing should always be informed by the FDA medication label. Information on this topic is found in the FDA medication label.
All doses and formulations of Abilify Maintena can be administered intramuscularly in the deltoid or gluteal muscle. Single dose vial kit – more dosing flexibility to administer lower doses: 160 mg (injection volume of 0.8 ml), 200 mg (injection volume of 1 ml), 300 mg (injection volume of 1.5 ml), or the standard (recommended starting and maintenance) dose of 400 mg (injection volume of 2 ml). This formulation should be utilized within 30 minutes of reconstitution. Single dose prefilled dual chamber syringe kits for 300 mg (injection volume of 1.5 ml) and 400 mg doses (injection volume of 2.0 ml) – fewer steps and components. Practical issues (including administration)
#AMBIFY ANDROID HOW TO#
Refer to this tip on how to address missed doses. American Psychiatric Association Publishing. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Aripiprazole long-acting-injection (Abilify Maintena, ARISTADA). VA Pharmacy Benefits Management Services. Recommended available dose formulations include 300 and 400 mg pre-filled vial kits (PI recommended maximum 400 mg).ĭose reduction may be necessary for CYP450 interactions of side effect intolerance.ġ. Steady-state concentrations achieved with the 200-mg LAI formulation were found to be below the apparent therapeutic range observed with 10-mg oral daily dosing. Steady-state concentrations achieved by the 300- and 400-mg LAI formulations were within apparent therapeutic range observed with oral aripiprazole doses of 10 and 20 mg. Provides maximum plasma concentration in 4–7 days, dependent on injection location, with deltoid injections achieving this sooner. Recommended starting and maintenance dose is 400 mg (or lower dose of 300mg for patients who have had adverse reactions) administered once monthly (no sooner than 26 days after the previous injection). Oral aripiprazole (10-20 mg/d) or another antipsychotic must be continued for the first 14 days following the initial aripiprazole LAI. Two weeks of oral overlap (at therapeutic range) recommended at the time of administration of first injection. No loading dose strategy is available. Once every four-week intramuscular injection only, which must be administered by a healthcare provider. #AMBIFY ANDROID TRIAL#
Due to its long half-life, establishing tolerability may require up to a two-week trial of oral aripiprazole.Prior to initiating Abilify Maintena, establish tolerability with oral aripiprazole in aripiprazole-naïve patients.It is FDA-indicated to treat adults with schizophrenia and bipolar disorder. It is the first of two formulations of LAI aripiprazole (the other is Aristada ). Abilify Maintena (aripiprazole) is a long-acting injectable (LAI) formulation of aripiprazole.